A scleral prosthesis includes an elongated body and an insert. The body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The insert is configured to be placed between the first portions and to substantially fill the empty space. The first portions are biased so that they maintain separation from one another without external interference but are configured to be pushed towards each other in order to reduce a width of the first end. The insert, when placed between the first portions, keeps the first portions separated and prevents the first portions from being pushed together and reducing the width of the first end.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The body includes (i) opposing first and second free ends and (ii) a pair of first portions that form the first end and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The scleral prosthesis also includes an insert configured to be placed between the first portions and to substantially fill the empty space. The insert, prior to insertion, includes one or more slots. The first portions include one or more ridges configured to engage with the one or more slots of the insert.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end of the body and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The scleral prosthesis also includes an insert configured to be placed between the first portions and to substantially fill the empty space. The body includes a convex upper surface extending lengthwise between the ends. The insert includes a convex upper surface extending lengthwise along the insert.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The elongated body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end of the body and part of a remainder of the body between the first and second ends. The first and second ends are wider than the remainder of the body. The first portions are separated by empty space such that the first portions meet at a point between the first and second ends and are not connected to each other between that point and the first end. The first end projects beyond one or more sides of the remainder of the body and angles back towards the second end. The second end projects beyond the one or more sides of the remainder of the body and angles back towards the first end.

A system for managing female incontinence includes a body of biocompatible material configured to fit between the labia minora and the vestibule floor, the body having a surface configured to occlude the urethral meatus, an adhesive carried on at least a first portion of the surface and configured to provide a sealing engagement between the body and the urethral meatus, and wherein at least the adhesive includes a water gradient silicone hydrogel.

Aspects of the disclosure relate to synthetic tissue or organ scaffolds and methods and compositions for promoting or maintaining their structural integrity. Aspects of the disclosure are useful to prevent scaffold damage (e.g., delamination) during or after implantation into a host. Aspects of the disclosure are useful to stabilize tissue or organ scaffolds that include electrospun fibers.

Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

A prosthetic heart valve for implant in a human. The valve includes a wireform with undulating inflow cusps and outflow commissure posts to which flexible leaflets attach and coapt in a flow area. Each leaflet may drape over the top of the wireform in the cusp area, but have tabs that each extend underneath the wireform at the commissure posts to be secured along with a tab of an adjacent leaflet. The prosthetic heart valve may also be a dual-wire wireform, with the leaflets sandwiched therebetween. One wireform may be larger than the other, with the leaflets extending over the smaller wireform. The smaller wireform may have commissures that bend radially outward from the larger wireform to provide structure to which the leaflet tabs attach.

Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.